CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6 - PubMed (original) (raw)
Comparative Study
CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6
L B von Weymarn et al. Xenobiotica. 2003 Jan.
Abstract
1. We investigated the total metabolism of coumarin by baculovirus (BV)-expressed CYP2A13 and compared it with metabolism by BV-expressed CYP2A6. The major coumarin metabolite formed by CYP2A13 was 7-hydroxycoumarin, which accounted for 43% of the total metabolism. The product of 3,4-epoxidation, o-hydroxyphenylacetaldehyde (o-HPA), accounted for 30% of the total metabolites. 2. The K(m) and V(max) for CYP2A13-mediated coumarin 7-hydroxylation were 0.48+/-0.07 micro m and 0.15+/-0.006 nmol min(-1) nmol(-1) CYP, respectively. The V(max) of coumarin 7-hydroxylation by CYP2A13 was about 16-fold lower than that of CYP2A6, whereas the K(m) was 10-fold lower. 3. In the mouse, there were two orthologues for CYP2A6: CYP2A4 and CYP2A5, which differed by only 11 amino acids. However, CYP2A5 is an efficient coumarin 7-hydroxylase, where as CYP2A4 is not. We report here that BV-expressed CYP2A4 metabolizes coumarin by 3,4-epoxidation. Two products of the 3,4-epoxidation pathway, o-HPA and o-hydroxyphenylacetic acid (o-HPAA), were detected by radioflow HPLC. 4. The K(m) and V(max) for the coumarin 3,4-epoxidation by CYP2A4 were 8.7+/-3.6 micro m and 0.20+/-0.04 nmol min(-1) nmol(-1) CYP, respectively. Coumarin 7-hydroxylation by CYP2A5 was more than 200 times more efficient than 3,4 epoxidation by CYP2A4.
Similar articles
- Coumarin metabolism by rat esophageal microsomes and cytochrome P450 2A3.
von Weymarn LB, Murphy SE. von Weymarn LB, et al. Chem Res Toxicol. 2001 Oct;14(10):1386-92. doi: 10.1021/tx010065v. Chem Res Toxicol. 2001. PMID: 11599930 - Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice.
Zhuo X, Gu J, Zhang QY, Spink DC, Kaminsky LS, Ding X. Zhuo X, et al. J Pharmacol Exp Ther. 1999 Feb;288(2):463-71. J Pharmacol Exp Ther. 1999. PMID: 9918546 - Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation.
He XY, Shen J, Hu WY, Ding X, Lu AY, Hong JY. He XY, et al. Arch Biochem Biophys. 2004 Jul 15;427(2):143-53. doi: 10.1016/j.abb.2004.03.016. Arch Biochem Biophys. 2004. PMID: 15196988 - CYP2A6: a human coumarin 7-hydroxylase.
Pelkonen O, Rautio A, Raunio H, Pasanen M. Pelkonen O, et al. Toxicology. 2000 Apr 3;144(1-3):139-47. doi: 10.1016/s0300-483x(99)00200-0. Toxicology. 2000. PMID: 10781881 Review. - CYP2A6: genetics, structure, regulation, and function.
Raunio H, Rahnasto-Rilla M. Raunio H, et al. Drug Metabol Drug Interact. 2012 May 5;27(2):73-88. doi: 10.1515/dmdi-2012-0001. Drug Metabol Drug Interact. 2012. PMID: 22706231 Review.
Cited by
- Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol.
Kramlinger VM, von Weymarn LB, Murphy SE. Kramlinger VM, et al. Chem Biol Interact. 2012 May 30;197(2-3):87-92. doi: 10.1016/j.cbi.2012.03.009. Epub 2012 Apr 1. Chem Biol Interact. 2012. PMID: 22486895 Free PMC article. - Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.
Blake LC, Roy A, Neul D, Schoenen FJ, Aubé J, Scott EE. Blake LC, et al. Pharm Res. 2013 Sep;30(9):2290-302. doi: 10.1007/s11095-013-1054-z. Epub 2013 Jun 12. Pharm Res. 2013. PMID: 23756756 Free PMC article. - Dietary Dihydromethysticin Increases Glucuronidation of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol in A/J Mice, Potentially Enhancing Its Detoxification.
Narayanapillai SC, von Weymarn LB, Carmella SG, Leitzman P, Paladino J, Upadhyaya P, Hecht SS, Murphy SE, Xing C. Narayanapillai SC, et al. Drug Metab Dispos. 2016 Mar;44(3):422-7. doi: 10.1124/dmd.115.068387. Epub 2016 Jan 7. Drug Metab Dispos. 2016. PMID: 26744252 Free PMC article. - CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5'(1')iminium ion.
von Weymarn LB, Retzlaff C, Murphy SE. von Weymarn LB, et al. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15. doi: 10.1124/jpet.112.195255. Epub 2012 Aug 6. J Pharmacol Exp Ther. 2012. PMID: 22869927 Free PMC article. - Effect of CYP2A13 active site mutation N297A on metabolism of coumarin and tobacco-specific nitrosamines.
Schlicht KE, Berg JZ, Murphy SE. Schlicht KE, et al. Drug Metab Dispos. 2009 Mar;37(3):665-71. doi: 10.1124/dmd.108.025072. Epub 2008 Dec 12. Drug Metab Dispos. 2009. PMID: 19074523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous